Endocrine therapy of breast cancer
Open Access
- 1 October 2002
- journal article
- review article
- Published by Elsevier in Annals of Oncology
- Vol. 13 (suppl_4) , 61-68
- https://doi.org/10.1093/annonc/mdf640
Abstract
1Department of Medicine, European Institute of Oncology, Milan, Italy; 2Oncology Institute of Southern Switzerland, Ospedale Civico, Lugano, Switzerland; 3Division of Medical Oncology, European Institute of Oncology, Milan, Italy; 4Harvard Medical School and Harvard School of Public Health, Dana-Farber Cancer Institute, Boston, MA, USAKeywords
This publication has 51 references indexed in Scilit:
- Adaptive hypersensitivity to estradiol: potential mechanism for secondary hormonal responses in breast cancer patientsThe Journal of Steroid Biochemistry and Molecular Biology, 2001
- EM-652 (SCH57068), a pure SERM having complete antiestrogenic activity in the mammary gland and endometriumThe Journal of Steroid Biochemistry and Molecular Biology, 2001
- Mechanisms of tamoxifen-induced apoptosisApoptosis, 2001
- Estrogen receptor beta--a new dimension in estrogen mechanism of actionJournal of Endocrinology, 1999
- Selective oestrogen receptor modulationEuropean Journal Of Cancer, 1999
- Correlation between plasma transforming growth factor-β1 and second primary breast cancer in a chemoprevention trialEuropean Journal Of Cancer, 1998
- Aromatase inhibitor development for treatment of breast cancerBreast Cancer Research and Treatment, 1995
- Effect of Tamoxifen on Serum Insulinlike Growth Factor I Levels in Stage I Breast Cancer PatientsJNCI Journal of the National Cancer Institute, 1990
- Anti-oestrogens induce the secretion of active transforming growth factor beta from human fetal fibroblastsBritish Journal of Cancer, 1990
- Evidence that transforming growth factor-β is a hormonally regulated negative growth factor in human breast cancer cellsCell, 1987